Notice: Undefined variable: option in
/var/www/vhosts/clinuvel.com/httpdocs/plugins/content/jwts.php on line
73
Notice: Undefined variable: option in
/var/www/vhosts/clinuvel.com/httpdocs/plugins/content/jwts.php on line
73
Notice: Undefined index: print in
/var/www/vhosts/clinuvel.com/httpdocs/plugins/content/jwts.php on line
81
Notice: Undefined index: format in
/var/www/vhosts/clinuvel.com/httpdocs/plugins/content/jwts.php on line
81
Notice: Undefined index: print in
/var/www/vhosts/clinuvel.com/httpdocs/plugins/content/jwts.php on line
139
Notice: Undefined index: format in
/var/www/vhosts/clinuvel.com/httpdocs/plugins/content/jwts.php on line
139
Clinuvel has raised over A$66million since 2006 to fund its clinical program for afamelanotide. The company has forecast that its current cash reserves are sufficient to fund afamelanotide to its first Marketing Authorisation Application.
| Latest Quarterly Report (Appendix 4C) | Q4 2011 - Calender Year |
|---|
| Cash and financial assets at end of Quarter |
A$ 11.752 million |
| Average operating cash outflows (Oct 1 - Dec 31 2011) |
A$ 1.14 million per month |
| Average net operating cash flows (Oct 1 - Dec 31 2011) |
A$ 0.91 million per month |
| Calender Quarter | Quarterly Operating Cash Outflows | Cash & Financial Assets at Hand |
|---|
| Q4 07 |
2.97 |
56.939 |
| Q1 08 |
2.81 |
52.997 |
| Q2 08 |
2.67 |
50.801 |
| Q3 08 |
3.53 |
46.268 |
| Q4 08 |
3.18 |
43.298 |
| Q1 09 |
3.35 |
39.387 |
| Q2 09 |
3.85 |
37.728 |
| Q3 09 |
3.76 |
35.542 |
| Q4 09 |
3.43 |
32.478 |
| Q1 10 |
3.05 |
29.359 |
| Q2 10 |
2.98 |
27.003 |
| Q3 10 |
2.69 |
24.678 |
| Q4 10 |
2.55 |
22.545 |
| Q1 11 |
2.86 |
20.226 |
| Q2 11 |
2.97 |
17.503 |
| Q3 11 |
3.63 |
14.604 |
| Q4 11 |
3.41 |
11.752 |
All figures rounded to A$m.
|
June 2011 |
June 2010 |
June 2009 |
June 2008 |
June 2007 |
June 2006 |
| Balance Sheet |
|
|
|
|
|
|
| Cash and financial assets at end of Quarter |
17.5 |
27.0 |
37.8 |
50.8 |
62.3 |
10.6 |
| Total Assets |
20.2 |
29.5 |
41.6 |
55.0 |
67.8 |
17.0 |
| Total Liabilities |
3.8 |
3.1 |
4.5 |
3.1 |
2.4 |
3.1 |
| Total Equity |
16.4 |
26.4 |
37.1 |
51.8 |
65.4 |
14.0 |
| P and L Statement |
|
|
|
|
|
|
| Net Profit (Loss) |
(11.4) |
(11.5) |
(15.4) |
(14.7) |
(9.2) |
(10.8) |
| Cash Flow Statement |
|
|
|
|
|
|
| Net Cash provided by (Used in) Operating activities |
(9.5) |
(11.8) |
(11.0) |
7.2 |
8.2 |
11.4 |
| End of Financial Year |
June 30 |
| Full Year Results Released |
By no later than August 31 |
| Q1 Results Released (Appendix 4C) |
By no later than April 30 |
| Q2 Results Released (Appendix 4C) |
By no later than July 31 |
| Q3 Results Released (Appendix 4C) |
By no later than October 31 |
| Q4 Results Released (Appendix 4C) |
By no later than January 31 |
| Half Yearly Report Released (Appendix 4D) |
By no later than February 28 |
| Capital Raisings (Last 5 years only) | $m Raised | # Share (m) | Price |
|---|
| May 2006 Placement |
$ 5.0 |
14.7 |
$0.34 |
| Sep 2006 Rights Issue and Placement |
$ 35.2 million |
91.4 |
$0.38 |
| Apr 2007 Placement |
$ 26.0 million |
24.3 |
$1.07 |
